MedPath

American Genomics, LLC

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:5

Trial Phases

2 Phases

Phase 1:1
Phase 3:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 3
4 (80.0%)
Phase 1
1 (20.0%)

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

Phase 3
Completed
Conditions
Anesthesia, Local
Interventions
Drug: Placebo
First Posted Date
2022-08-16
Last Posted Date
2024-10-09
Lead Sponsor
American Genomics, LLC
Target Recruit Count
249
Registration Number
NCT05501860
Locations
🇺🇸

American Genomics Site 1, Newport Beach, California, United States

🇺🇸

American Genomics Site 2, McAllen, Texas, United States

A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population

Phase 3
Completed
Conditions
Anesthesia, Local
Interventions
First Posted Date
2022-04-13
Last Posted Date
2023-10-25
Lead Sponsor
American Genomics, LLC
Target Recruit Count
61
Registration Number
NCT05325853
Locations
🇺🇸

American Genomics Site 2, McAllen, Texas, United States

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

Phase 3
Completed
Conditions
Anesthesia, Local
Interventions
Drug: Placebo
First Posted Date
2021-04-02
Last Posted Date
2024-10-10
Lead Sponsor
American Genomics, LLC
Target Recruit Count
120
Registration Number
NCT04829344
Locations
🇺🇸

American Genomics Site 2, McAllen, Texas, United States

An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2021-02-18
Last Posted Date
2022-04-29
Lead Sponsor
American Genomics, LLC
Target Recruit Count
14
Registration Number
NCT04759339
Locations
🇺🇸

Celerion, Lincoln, Nebraska, United States

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

Phase 3
Completed
Conditions
Anesthesia, Local
Interventions
Drug: Placebo
First Posted Date
2020-08-14
Last Posted Date
2022-09-28
Lead Sponsor
American Genomics, LLC
Target Recruit Count
120
Registration Number
NCT04513652
Locations
🇺🇸

American Genomics Site 1, Newport Beach, California, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath